JP3257091B2 - Anti-skin cancer agent or food - Google Patents

Anti-skin cancer agent or food

Info

Publication number
JP3257091B2
JP3257091B2 JP32270392A JP32270392A JP3257091B2 JP 3257091 B2 JP3257091 B2 JP 3257091B2 JP 32270392 A JP32270392 A JP 32270392A JP 32270392 A JP32270392 A JP 32270392A JP 3257091 B2 JP3257091 B2 JP 3257091B2
Authority
JP
Japan
Prior art keywords
whey
skin cancer
food
soybean
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP32270392A
Other languages
Japanese (ja)
Other versions
JPH06145061A (en
Inventor
山本  茂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Oil Co Ltd
Original Assignee
Fuji Oil Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Oil Co Ltd filed Critical Fuji Oil Co Ltd
Priority to JP32270392A priority Critical patent/JP3257091B2/en
Publication of JPH06145061A publication Critical patent/JPH06145061A/en
Application granted granted Critical
Publication of JP3257091B2 publication Critical patent/JP3257091B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の目的】[Object of the invention]

【産業上の利用分野】本発明は、大豆ホエイ画分を有効
成分とする抗皮膚癌剤及び抗皮膚癌性の機能食品に関す
る。
The present invention relates to an anti-skin cancer agent and an anti-skin cancer functional food containing a soy whey fraction as an active ingredient.

【0002】[0002]

【従来の技術】[Prior art]

(1) 発明の背景 大豆ホエイ成分は、ダイズ子実中の全蛋白質の7〜9%
を占め、トリプシンインヒビター、へマグルチニン、ゴ
イトロジェン、サポニン、リポキシゲナーゼ、β−アミ
ラーゼ、プロテアーゼ、フィターゼなど様々な生理活性
物質を含む。これら諸成分の中、サポニンはトリテルペ
ノイド系アグリコンを含み、生理活性物質の原料として
利用できる可能性があるが、今のところ有効には利用さ
れていない。
(1) Background of the Invention Soy whey component accounts for 7 to 9% of the total protein in soybean grain.
And various bioactive substances such as trypsin inhibitor, hemagglutinin, goitrogen, saponin, lipoxygenase, β-amylase, protease, and phytase. Among these components, saponin contains a triterpenoid-based aglycone and may be used as a raw material of a physiologically active substance, but has not been effectively used so far.

【0003】更にトリプシンインヒビターは、トリプシ
ンの活性を阻害し、またヘマグルチニンは、小腸上皮細
胞粘膜を障害するなど、いずれも好ましくない“抗栄養
因子”であるとされている。これらの事実もまた、大豆
ホエイ画分の有効理由を妨げる消極的理由となってい
る。
Further, trypsin inhibitors inhibit the activity of trypsin, and hemagglutinin is considered to be an unfavorable “antitrophic factor”, such as damaging the intestinal epithelial cell mucosa. These facts are also passive reasons that hinder the validity of soy whey fractions.

【0004】もっとも、ダイズ子実成分には制癌作用の
あることが報告されている。例えば、Troll ら(Carcino
genesis,1, 469-472(1980)は、全大豆蛋白質を与えたラ
ットでは乳癌の発生が抑制されることを観察している。
またBecker(Carcinogenesis.2.1213-1214(1981) は、26
%カゼイン食で 100%観察されるマウスの肝臓癌が、カ
ゼインの約5%を全大豆蛋白質で置き換えると完全に抑
制されたと報告している。これらの研究結果から、大豆
蛋白成分中には癌の成長を阻害する何らかの因子が存在
するものと想像され、 上記Troll(J.N.C.I. 7, 1245-125
0(1984) は、制癌作用の実体が大豆蛋白に夾雑するプロ
テアーゼインヒビターであろうことを疫学的に考察して
いる。
However, it has been reported that the soybean grain component has an anticancer effect. For example, Troll et al. (Carcino
genesis, 1, 469-472 (1980) observed that the development of breast cancer was suppressed in rats fed whole soy protein.
Becker (Carcinogenesis.2.1213-1214 (1981)
He reports that 100% of the liver cancer in mice observed on a% casein diet was completely suppressed when about 5% of the casein was replaced with whole soy protein. From these research results, it is supposed that there is some factor in soybean protein component that inhibits cancer growth, and Troll (JNCI 7, 1245-125)
0 (1984) epidemiologically considers that the anticancer substance may be a protease inhibitor contaminating soy protein.

【0005】しかしながら、このようにプロテアーゼイ
ンヒビターの制癌的作用が評価される一方では、プロテ
アーゼインヒビターの範疇に属するトリプシンインヒビ
ターを含む食餌で長期間飼育したラットでは膵癌が発生
し易いとの相反する報告も存在する(例えばMaGuinenes
s et.al.,Scand. J. Gastroenterol. 15, 497-502(198
0) 等) のみならず、プロテアーゼインヒビターが対応
するプロテアーゼと結合する結果、栄養的に悪い影響が
出るであろうことが推測される。しかし、特に大豆ホエ
イ成分の薬理的作用に関する研究はこれまで存在してい
ない。しかもホエイはダイズ蛋白の抽出に際し副生物と
して多量に傍生するものであるから、その用途開発は、
農産加工産業上も重要な意義を有する。
[0005] However, while the anticancer effects of protease inhibitors are evaluated as described above, there are conflicting reports that pancreatic cancer is likely to occur in rats bred for a long time on a diet containing trypsin inhibitor, which belongs to the category of protease inhibitors. (For example, MaGuinenes
et.al., Scand. J. Gastroenterol. 15, 497-502 (198
0) etc.), it is speculated that binding of the protease inhibitor to the corresponding protease will have a negative nutritional effect. However, there is no study on the pharmacological action of soy whey components. In addition, whey is a by-product in the extraction of soybean protein in a large amount as a by-product.
It also has important significance in the agricultural processing industry.

【0006】[0006]

【発明が解決しようとする課題】以上の実情に鑑み、本
発明は、大豆ホエイ画分を医薬乃至健康食品の素材とし
て有効利用を図ることを目的とする。
SUMMARY OF THE INVENTION In view of the above circumstances, an object of the present invention is to effectively utilize a soybean whey fraction as a raw material for medicines or health foods.

【0007】[0007]

【課題を解決するための手段】 発明の概念 そこで本発明者は、大豆ホエイの有効利用という観点か
ら同画分の薬効及び栄養的副作用につき検討を進めた結
果、本画分が動物の皮膚癌に対して有効であるのみなら
ず、栄養的にも格別の有害作用を示さないことを認め、
本発明を完成した。
Means for Solving the Problems Concept of the Invention The present inventor has studied the medicinal and nutritional side effects of the same fraction from the viewpoint of effective use of soybean whey. Not only is effective against but also does not show any particular nutritional adverse effects,
The present invention has been completed.

【0008】 概要 即ち、本発明は、大豆ホエイ画分を有効成分とする抗皮
膚癌剤及び大豆ホエイ画分を機能成分とする抗皮膚癌性
の食品を要旨とするものである。以下、発明者らが本発
明に到達するに至った実験事実を記載する。
[0008] That is, the present invention provides an anti-skin cancer agent containing a soy whey fraction as an active ingredient and an anti-skin cancer food containing a soy whey fraction as a functional ingredient. Hereinafter, the experimental facts that led the inventors to reach the present invention will be described.

【0009】(1) 実験 実験1(薬剤の調製) 大豆ホエイ200kg をpH5〜6に調整し、50℃で限外濾過
して濃縮した。限外濾過膜としてダイセル化学製DU50
(分画分子量40000,管状モジュール)を用い、20倍に濃
縮した。得られた濃縮ホエイを苛性ソーダでpH7に調整
後、噴霧乾燥して、濃縮ホエイ粉末500gを得た。 [分析値] 粗蛋白含量約61.4%(ケールダール法によ
る) 全糖21.5%(フェノール硫酸法による) トリプシンインヒビター活性490 U/g(基質BAPA使
用,Katadeの方法による)
(1) Experiment Experiment 1 (Preparation of a drug) 200 kg of soybean whey was adjusted to pH 5 to 6, and concentrated by ultrafiltration at 50 ° C. DU50 made by Daicel Chemical as an ultrafiltration membrane
(Fraction molecular weight: 40,000, tubular module) and concentrated 20-fold. The obtained concentrated whey was adjusted to pH 7 with caustic soda and then spray-dried to obtain 500 g of concentrated whey powder. [Analytical value] Crude protein content about 61.4% (by the Kjeldahl method) Total sugar 21.5% (by the phenol-sulfuric acid method) Trypsin inhibitor activity 490 U / g (using the substrate BAPA, using the Katade method)

【0010】実験2(動物試験) 方法 ICR系雄マウス(6週令)30匹を2群に分け、20%分
離大豆蛋白質(SPI;フジプロRR)食あるいは18%S
PIに前例で得た濃縮ホエイ粉末2%を含む食餌を全期
間与えた。全ての食餌には、大豆油5%、ミネラル混合
物5%(オリエンタル酵母社製)、ビタミン混合物1%
(オリエンタル酵母社製)、セルロース2%及びDL−
メチオニン 0.4%を含有させ、残余は炭水化物(α−ト
ウモロコシ澱粉:砂糖=2:1)とした。
Experiment 2 (Animal test) Method 30 ICR male mice (6 weeks old) were divided into two groups, and 20% isolated soybean protein (SPI; Fujipro RR ) diet or 18% S
PIs were fed a diet containing 2% of the concentrated whey powder obtained in the previous example for the entire period. All diets include 5% soybean oil, 5% mineral mix (Oriental Yeast), 1% vitamin mix
(Manufactured by Oriental Yeast), cellulose 2% and DL-
Methionine was contained at 0.4%, and the balance was carbohydrate (α-corn starch: sugar = 2: 1).

【0011】実験食1週間目に動物の背中の毛を剃り、
約半数のマウスにはそこに初発因子である7,12−ジメ
チルベンゾアントラセンのアセトン溶液(100 μg/0.
1ml)を塗布した。該塗布部位の毛は、その後、2週間毎
に鋏で剪除した。なお、マウスは1ケージに3匹飼育し
た。体重及び食物摂取量を毎週測定した。
One week after the experimental meal, the animal's back was shaved,
Approximately half of the mice have an acetone solution of 7,12-dimethylbenzoanthracene (100 μg / 0.
1 ml) was applied. The hair at the application site was then sheared every two weeks with scissors. In addition, three mice were bred in one cage. Body weight and food intake were measured weekly.

【0012】実験群のマウスには、初発因子塗布1週間
後からプロモーターであるフォルボール−12−ミリステ
イト−13−アセテイト(TPA)のアセトン溶液(2.5
μg/0.1ml)を実験の全期間に亙り、各週2回塗布し続け
た。毎週直径1mmφ以上の腫瘍について数と体積を測定
した。腫瘍の体積は、ノギスを用いて縦(a) 、横(b)、
高さ(c) を測定し、a×b×cπ/6の計算式に基づい
て計算した。
One week after the application of the initial factor, mice in the experimental group were given a solution of phorbol-12-myristate-13-acetate (TPA) in acetone (2.5 A).
μg / 0.1 ml) was applied twice a week for the entire duration of the experiment. The number and volume of the tumors having a diameter of 1 mmφ or more were measured every week. Tumor volume can be measured using calipers vertically (a), horizontal (b),
The height (c) was measured and calculated based on the formula of a × b × cπ / 6.

【0013】 結果及び考察 図1に飼育第14週における体重と食物摂取量を示した。
SPI群及びホエイ群の間には、体重及び食物摂取量の
何れにも有意差は見られなかった。
Results and Discussion FIG. 1 shows body weight and food intake in the 14th week of rearing.
No significant differences in body weight and food intake were found between the SPI group and the whey group.

【0014】図2に初発因子塗布後14週目の腫瘍マウス
の割合を示した。SPI群及びホエイ群の割合はそれぞ
れ80%及び47%で、ホエイ群で有意に低かった。
FIG. 2 shows the proportion of tumor mice 14 weeks after application of the initial factor. The proportions of the SPI group and the whey group were 80% and 47%, respectively, which were significantly lower in the whey group.

【0015】図3に担癌マウス1匹あたりの腫瘍の個数
を示した。SPI群及びホエイ群でそれぞれ 4.7個及び
1.6個で、ホエイ群が有意に低かった。
FIG. 3 shows the number of tumors per tumor-bearing mouse. 4.7 each in SPI group and whey group
At 1.6, the whey group was significantly lower.

【0016】図4に担癌マウスの腫瘍の体積を示した。
SPI群及びホエイ群の値はそれぞれ50及び8mm3 で、
ホエイ群で有意に小さかった。
FIG. 4 shows the tumor volume of the tumor-bearing mouse.
The values for the SPI group and the whey group were 50 and 8 mm 3 , respectively.
It was significantly smaller in the whey group.

【0017】 考察 本実験の結果は、濃縮ホエイ粉末を食餌に添加すること
により、化学発癌剤を塗布したマウスの皮膚癌が顕著に
抑制されることを示している。本実験から導かれた特筆
すべき知見は、試験動物の食物摂取量や成長(体重増
加)を損なわない程度の少量の大豆ホエイ画分の投与で
も、充分な皮膚癌の発癌抑制作用が見られたことであ
る。従って、これを少量づつ持続的に摂取することによ
り、皮膚癌乃至その前癌状態の発生を抑制又は抑止する
ことができよう。因に、皮膚癌の発生と照射紫外線量と
の間には密接な相関が認められており、メタンガス等、
人為的には制御不能な要因によるオゾン層の破壊進行に
伴い、将来深刻な健康問題と化するであろうことが予測
されるから、大豆ホエイ画分を抗皮膚癌剤乃至抗皮膚癌
性機能食品として利用することは、他方産業廃棄物の減
量とも関連する一石二鳥の名案となる。
DISCUSSION The results of this experiment indicate that the addition of concentrated whey powder to diet significantly suppresses skin cancer in mice coated with a chemical carcinogen. A remarkable finding derived from this experiment is that the administration of a small amount of soy whey fraction that does not impair the food intake and growth (weight gain) of test animals shows a sufficient inhibitory effect on skin carcinogenesis. That is. Therefore, by continuously ingesting a small amount thereof, the occurrence of skin cancer or its precancerous state could be suppressed or suppressed. However, a close correlation has been observed between the occurrence of skin cancer and the amount of irradiated ultraviolet light, such as methane gas.
Since it is predicted that the ozone layer destruction due to artificially uncontrollable factors will become a serious health problem in the future, soybean whey fraction is used as an anti-skin cancer agent or anti-skin cancer function. Use as food is a good idea for two birds with one stone, which on the other hand is related to the reduction of industrial waste.

【0018】(1) 大豆ホエイ画分 本発明において、“大豆ホエイ画分”というのは、原則
として脱脂大豆などの濃縮大豆蛋白原料を、水又はアル
カリ性水で抽出した主としてグリシニンからなる抽出物
を、等電点(pH約4.5)付近に変じることにより析出した
沈澱を除いた上清を意味するが、夾雑する低分子物質
(主として塩類、単糖及び少糖類等)を除去したもので
あることが好ましい。限外濾過膜による濾過は、比較的
簡単に脱塩、脱糖のみならず脱水、濃縮の目的を達成で
きるので、発明目的上有利である。濾過膜の性能として
は限界分子量1〜4万程度のものを選べばよい。
(1) Soy Whey Fraction In the present invention, the term “soy whey fraction” means, in principle, a concentrated soybean protein material such as defatted soybean, which is extracted from water or alkaline water and mainly composed of glycinin. , Which means the supernatant from which the precipitate precipitated by changing to around the isoelectric point (pH about 4.5) is removed, but from which contaminating low molecular substances (mainly salts, monosaccharides and oligosaccharides) are removed. Is preferred. Filtration with an ultrafiltration membrane is advantageous for the purpose of the invention, because it can achieve the purpose of dehydration and concentration as well as desalting and desalting relatively easily. The performance of the filtration membrane may be selected from those having a limit molecular weight of about 10,000 to 40,000.

【0019】以上の大豆蛋白からの大豆ホエイ画分の分
離及び精製操作においては、トリプシンインヒビターの
分解を防止するため、成るべく加熱を避けることが望ま
しい。但し水溶液状態では保存性がないので、噴霧乾
燥、凍結乾燥などの緩和な乾燥手段により脱水状態とし
て保存すべきである。
In the above-described separation and purification of the soybean whey fraction from soybean protein, it is desirable to avoid heating as much as possible in order to prevent the decomposition of the trypsin inhibitor. However, since there is no preservability in an aqueous solution state, it should be stored in a dehydrated state by a mild drying means such as spray drying and freeze drying.

【0020】(2) 投与形態 本発明に係る抗皮膚癌剤は、薬剤として単独で若しくは
他の薬剤や賦形剤と混合して、又は食品として任意の食
品中に配合して投与される。好適な薬剤の剤型は錠剤又
は顆粒の形態であるが、その他、水剤、エリキサー、シ
ロップなどの液剤の形にしてもよい。薬剤とする場合、
各種のビタミン、ミネラル等の副栄養素を共存させるの
が好ましく、特にチアミン、リボフラビン、ニコチン酸
アミド、、アデロキシン、パントテン酸、葉酸などのビ
タミンB類、ビタミンC、ビタミンE、グルタチオンな
どのビタミン類乃至その関連物質、及びカルシウム、
鉄、リンなどのミネラルの水溶性塩類は、栄養的にも配
合が好ましい成分である。
(2) Dosage Form The anti-skin cancer agent according to the present invention is administered alone as a drug or as a mixture with other drugs or excipients or as a food mixed with any food. Suitable pharmaceutical forms are tablets or granules, but may also be in the form of solutions such as solutions, elixirs and syrups. When it is a drug,
It is preferable to coexist various vitamins and minor nutrients such as minerals, especially vitamins B such as thiamine, riboflavin, nicotinamide, adeloxin, pantothenic acid, folic acid, vitamins such as vitamin C, vitamin E, glutathione and the like. Its related substances, and calcium,
Water-soluble salts of minerals such as iron and phosphorus are components that are preferably formulated nutritionally.

【0021】また食品として配合する場合は、穀粉、澱
粉等の炭水化物、大豆蛋白、肉類等の蛋白素材及び/又
は油脂類と共に、菓子類、パン類、麺類、米飯、調味
料、香辛料、乳製品、惣菜などに配合できる。栄養成分
の消化・吸収を阻害しないため、配合量は食品中の全蛋
白の10%を超えないことが望ましい。散剤又は顆粒剤の
形態は、発明剤を食品素材中に配合するのに便利であ
る。この場合、例えばグルテリン、ゼイン又はホルデイ
ンの如きプロラミン蛋白からなる消化性皮膜によって大
豆ホエイ画分の表面を被覆しておくことが該画分の吸湿
性を低減すると共に、該画分の不快な味をマスクするの
に有利である。因に、このようなコーティング処理は、
錠剤化工程における顆粒の被覆にも適用できる。
When formulated as foods, confectionery, breads, noodles, cooked rice, seasonings, spices, dairy products, along with carbohydrates such as flour and starch, protein materials such as soy protein, meat and / or fats and oils. , Can be blended in side dishes. In order not to inhibit digestion and absorption of nutrients, it is desirable that the compounding amount does not exceed 10% of the total protein in the food. The powder or granule form is convenient for incorporating the inventive agent into a food material. In this case, coating the surface of the soybean whey fraction with a digestible film composed of a prolamin protein such as glutelin, zein or hordein reduces the hygroscopicity of the fraction and the unpleasant taste of the fraction. This is advantageous for masking. By the way, such a coating process,
It can also be applied to the coating of granules in the tableting process.

【0022】[0022]

【作用】本発明剤の有効成分と考えられるトリプシンイ
ンヒビターは、対蛋白当たり少量の摂取では栄養吸収を
余り阻害することなしに、経口的に皮膚癌の発生を抑制
する作用がある。このため、本剤を健康食品的に日々服
用し又は食品素材若しくは完成食品中に添加することに
よって、皮膚癌の発生を未然に防止できる。
The trypsin inhibitor, which is considered to be an active ingredient of the agent of the present invention, has an effect of suppressing the occurrence of skin cancer orally without taking much inhibition of nutrient absorption when taken in a small amount per protein. Therefore, by taking this agent daily as a health food or adding it to a food material or finished food, skin cancer can be prevented from occurring.

【0023】[0023]

【実施例】【Example】

実施例1 ゼラチン25重量部(以下同様)、ステアリン酸50部、ペ
クチン10部、乳糖400部、バレイショ澱粉515 部、チア
ミン10部、L−アスコルビン酸100 部、グリセロリン酸
カルシウム100 部及び実験1の濃縮ホエイ粉末300 部を
湿式法により整粒後、打錠機を用いて1錠当たり500mg
の裸錠に製錠した。
Example 1 25 parts by weight of gelatin (the same applies hereinafter), 50 parts of stearic acid, 10 parts of pectin, 400 parts of lactose, 515 parts of potato starch, 10 parts of thiamine, 100 parts of L-ascorbic acid, 100 parts of calcium glycerophosphate and concentration of Experiment 1 After sizing 300 parts of whey powder by wet method, use a tableting machine to make 500 mg per tablet.
Was made into a naked tablet.

【0024】以上の裸錠を糖衣機中に容れ、回転させな
がらシェラック/エタノ−ル溶液で下掛けした後、常法
に従ってアラビアゴム及び二酸化チタンを含む白糖シロ
ップによる本掛け及びワックスによるポリッシングを行
い、抗皮膚癌作用及び栄養強化作用を有する健康食品の
糖衣錠剤を得た。
The above-mentioned naked tablet is placed in a sugar-coating machine, and is hanged with a shellac / ethanol solution while rotating. Then, the tablet is stabbed with white sugar syrup containing gum arabic and titanium dioxide and polished with wax according to a conventional method. Thus, a sugar-coated tablet of health food having an anti-skin cancer action and a nutrition-enhancing action was obtained.

【0025】実施例2 市販のヨーグルト味ドリンクベース100 gに実験1で得
た濃縮ホエイ粉末を2%の割合で混ぜて大豆ホエイ画分
入りドリンクベースを得た。このドリンクベースを牛乳
に対し適宜の混合すると、ヨーグルト風味を有する美味
な健康飲料が得られる。
Example 2 The concentrated whey powder obtained in Experiment 1 was mixed with 100 g of a commercially available yogurt taste drink base at a ratio of 2% to obtain a drink base containing a soybean whey fraction. When this drink base is appropriately mixed with milk, a delicious health drink having a yogurt flavor can be obtained.

【0026】実施例3 実験1の大豆ホエイ画分100 部にグリセロリン酸カルシ
ウム10部及び澱粉90部を加え、乾燥気流中緊密に混合し
た。これを流動層造粒乾燥機内に入れ、別途調製したゼ
インの70%エタノール溶液を多数回に分けて散布、乾燥
する操作を繰り返し、最後に溶媒が揮散し終わる迄コー
ティング処理した後、20メッシュ通、80メッシュ不通の粒度品を
分級して集めた。
Example 3 To 100 parts of the soy whey fraction of Experiment 1, 10 parts of calcium glycerophosphate and 90 parts of starch were added and mixed in a dry air stream. This was put into a fluidized bed granulation dryer, and the operation of spraying and drying a separately prepared 70% ethanol solution of zein in a large number of times was repeated. Finally, the coating treatment was performed until the solvent was completely volatilized. , An 80 mesh impervious particle size was classified and collected.

【0027】以上の顆粒状製品は、吸湿し難く、かつ不
快な味や臭気を有しないから、パン、ケーキ、ビスケッ
ト等の穀類加工食品の素材、てんぷら用衣液、各種ルー
の素材、ハンバーグ、ソーセージ等の加工肉製品用バイ
ンダーなどの成分として日常的に摂取するのに適し、皮
膚癌の予防のみならずカルシウム分の補給にも役立つ。
The above granular products are hard to absorb moisture and do not have unpleasant taste or odor. Therefore, materials for processed cereals such as bread, cake, biscuit, etc., clothing for tempura, various roux materials, hamburger, It is suitable for daily ingestion as a component such as a binder for processed meat products such as sausage, and is useful not only for prevention of skin cancer but also for supplementation of calcium.

【0028】[0028]

【発明の効果】以上説明した通り、本発明は従来産業廃
棄物視されていた大豆ホエイを抗皮膚癌性医薬乃至健康
食品として有効利用する用途を開発し得たことにより、
大豆蛋白製造産業の発展及び健康の保持に貢献しうる。
As described above, the present invention has developed a use of soybean whey, which has been regarded as industrial waste, as an anti-skin cancer drug or health food.
It can contribute to the development of the soybean protein manufacturing industry and maintenance of health.

【図面の簡単な説明】[Brief description of the drawings]

【図1】飼育第14週における体重と食物摂取量の関係を
示すグラフ
FIG. 1 is a graph showing the relationship between body weight and food intake during the 14th week of breeding.

【図2】初発因子塗布後14週目の腫瘍マウスの割合を示
すグラフ
FIG. 2 is a graph showing the percentage of tumor mice at 14 weeks after application of initial factors.

【図3】担癌マウス1匹あたりの腫瘍の個数を示すグラ
FIG. 3 is a graph showing the number of tumors per tumor-bearing mouse.

【図4】担癌マウスの腫瘍の体積を示すグラフ (以上の各グラフは、対照動物との対比において描画さ
れている。)
FIG. 4 is a graph showing the tumor volume of tumor-bearing mice (the above graphs are drawn in comparison with control animals).

───────────────────────────────────────────────────── フロントページの続き (58)調査した分野(Int.Cl.7,DB名) A61K 35/78 A23L 1/48 BIOSIS(STN) CA(STN) MEDLINE(STN)──────────────────────────────────────────────────続 き Continued on the front page (58) Field surveyed (Int. Cl. 7 , DB name) A61K 35/78 A23L 1/48 BIOSIS (STN) CA (STN) MEDLINE (STN)

Claims (1)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】大豆ホエイ画分を有効成分とする抗皮膚癌
剤。
An anti-skin cancer agent comprising a soy whey fraction as an active ingredient.
JP32270392A 1992-11-06 1992-11-06 Anti-skin cancer agent or food Expired - Fee Related JP3257091B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP32270392A JP3257091B2 (en) 1992-11-06 1992-11-06 Anti-skin cancer agent or food

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32270392A JP3257091B2 (en) 1992-11-06 1992-11-06 Anti-skin cancer agent or food

Publications (2)

Publication Number Publication Date
JPH06145061A JPH06145061A (en) 1994-05-24
JP3257091B2 true JP3257091B2 (en) 2002-02-18

Family

ID=18146681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP32270392A Expired - Fee Related JP3257091B2 (en) 1992-11-06 1992-11-06 Anti-skin cancer agent or food

Country Status (1)

Country Link
JP (1) JP3257091B2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) * 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products

Also Published As

Publication number Publication date
JPH06145061A (en) 1994-05-24

Similar Documents

Publication Publication Date Title
KR101780079B1 (en) Stevia extract or steviol for hair care
JP5112865B2 (en) Composition for preventing or treating hemoglobinuria or myoglobinuria
JPWO2008108395A1 (en) Method for producing extract containing osteocalcin
JPH0124768B2 (en)
WO2006108345A1 (en) Fruit vinegar-egg powder and composition containing vinegar-egg powder
KR101896024B1 (en) Functional food compositions comprising extracts of Garcinia Cambogia as active ingredients and method for preparing the same
JP3257091B2 (en) Anti-skin cancer agent or food
NL7905993A (en) HYPO-BETA-LIPOPROTEINEMIC DIETECTIC, METHOD FOR THE PREPARATION AND USE THEREOF.
CA2692371A1 (en) Anti-fatigue composition
JPH11180869A (en) Blood lipid improving agent, cyclic amp phosphodiesterase inhibitor, drink and food, and skin preparation for external use
JPH07277991A (en) Mineral absorption-stimulating agent
JP5405067B2 (en) Antioxidant composition containing bee pup
WO2001091762A1 (en) Zinc-supplementary compositions for oral administration
US20220273618A1 (en) Protein hydrolysates
JP2017088549A (en) Endurance enhancers
JP6518744B2 (en) Oral composition
WO2015190682A1 (en) Composition for growth promotion, containing coumaric acid as active ingredient
JP2005255574A (en) IgA-PRODUCTION-LEVELING AGENT AND STRESS DISEASE-PREVENTING AND/OR TREATING COMPOSITION CONTAINING THE SAME
JP3248170B2 (en) Food containing chondroitin sulfate protein complex
JP2000139411A (en) Food and drink including isoflavone together with peptide
NL1017717C2 (en) Combined plant coagulate composition, method for its preparation and use.
JP2002255832A (en) Mineral absorption-promoting agent and anemia- improving agent
JP3209375B2 (en) Alcoholic liver disorder reducer
JPH09132531A (en) Composition for additive to liquid food and liquid food
JP3537098B2 (en) Alcoholic liver disorder reducer

Legal Events

Date Code Title Description
FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071207

Year of fee payment: 6

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081207

Year of fee payment: 7

LAPS Cancellation because of no payment of annual fees